Literature DB >> 23044809

Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.

Claudia Cardoso1, Ana L Alves, Fátima Augusto, Ricardo Freire, Carlos Quintana, Matilde Gonçalves, Ana P Oliveira.   

Abstract

INTRODUCTION: Occult hepatitis B virus (HBV) infection, defined as the presence of HBV DNA in the liver (with detectable or undetectable HBV DNA in the serum), has been reported in patients with chronic hepatitis C. Some data suggest its association with a more severe liver disease and a worse response to interferon therapy in this subgroup of patients. However, the clinical significance of this condition is still under debate. AIM: To determine the prevalence of occult HBV infection and its clinical significance in patients with chronic hepatitis C liver disease.
MATERIALS AND METHODS: A prospective analysis of consecutive outpatients with chronic hepatitis C who underwent a liver biopsy recruited between January 2008 and June 2011 was carried out. Data included patient's sex and age, source of hepatitis C virus (HCV) infection, HCV genotype and viral load, presence of serologic markers of previous HBV infection, HBV DNA presence in the liver, histologic findings, and response to interferon and ribavirin treatment. HBV DNA and HCV RNA detection were carried out using a sensitive commercially available PCR kit. HBV DNA was tested in liver samples using a nested PCR procedure.
RESULTS: One hundred patients were included, 73% men, mean age 49 ± 11.9 years. Most patients had a genotype 1, with a high viral load, HCV infection. Of the patients, 33% had HBV serologic markers of past infection. The presence of HBV DNA in liver samples was found in 57% of the patients. No statistically significant difference in the epidemiological, histological, or virological or response to therapy data was found in patients with occult HBV infection.
CONCLUSION: Occult HBV infection occurred in a high percentage of patients but was not clinically significant.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23044809     DOI: 10.1097/MEG.0b013e328359fe54

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Comparison of Patients Monoinfected with Hepatitis C Virus and Coinfected with Hepatitis B/C in the Amazon Region of Brazil.

Authors:  Regiane M A Sampaio; Paola Eduarda F Dantas; Maria Inês C da Silva; Joseane R da Silva; Patrícia F Nunes; Amanda C Gomes; Luisa C Martins
Journal:  Viruses       Date:  2022-04-21       Impact factor: 5.818

2.  Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases.

Authors:  X-L Wei; M-Z Qiu; Y Jin; Y-X Huang; R-Y Wang; W-W Chen; D-S Wang; F Wang; H-Y Luo; D-S Zhang; F-H Wang; Y-H Li; R-H Xu
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

Review 3.  The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.

Authors:  Dimitris Konstantinou; Melanie Deutsch
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

4.  Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection.

Authors:  Junhyeon Cho; Sang Soo Lee; Yun Suk Choi; Yejoo Jeon; Jung Wha Chung; Joo Yeong Baeg; Won Keun Si; Eun Sun Jang; Jin-Wook Kim; Sook-Hyang Jeong
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

5.  Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy.

Authors:  Fabio Tramuto; Carmelo Massimo Maida; Giuseppina M E Colomba; Paola Di Carlo; Francesco Vitale
Journal:  Biomed Res Int       Date:  2013-08-26       Impact factor: 3.411

Review 6.  HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation.

Authors:  Marianna G Mavilia; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2018-07-06

Review 7.  Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).

Authors:  Mariantonietta Pisaturo; Margherita Macera; Loredana Alessio; Federica Calò; Nicola Coppola
Journal:  Viruses       Date:  2019-09-13       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.